- Home
- MAC vs ZLAB Comparison
MAC vs ZLAB Comparison
Compare MAC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAC
- ZLAB
- Stock Information
- Founded
- MAC 1964
- ZLAB 2013
- Country
- MAC United States
- ZLAB China
- Employees
- MAC N/A
- ZLAB N/A
- Industry
- MAC Real Estate Investment Trusts
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- MAC Real Estate
- ZLAB Health Care
- Exchange
- MAC Nasdaq
- ZLAB Nasdaq
- Market Cap
- MAC 3.7B
- ZLAB 3.5B
- IPO Year
- MAC 1994
- ZLAB 2017
- Fundamental
- Price
- MAC $14.98
- ZLAB $29.24
- Analyst Decision
- MAC Hold
- ZLAB Buy
- Analyst Count
- MAC 12
- ZLAB 4
- Target Price
- MAC $18.20
- ZLAB $47.37
- AVG Volume (30 Days)
- MAC 1.7M
- ZLAB 1.2M
- Earning Date
- MAC 05-12-2025
- ZLAB 05-08-2025
- Dividend Yield
- MAC 4.53%
- ZLAB N/A
- EPS Growth
- MAC N/A
- ZLAB N/A
- EPS
- MAC N/A
- ZLAB N/A
- Revenue
- MAC $899,298,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- MAC $1.58
- ZLAB $44.43
- Revenue Next Year
- MAC N/A
- ZLAB $48.68
- P/E Ratio
- MAC N/A
- ZLAB N/A
- Revenue Growth
- MAC 5.01
- ZLAB 43.72
- 52 Week Low
- MAC $12.48
- ZLAB $15.65
- 52 Week High
- MAC $22.27
- ZLAB $39.77
- Technical
- Relative Strength Index (RSI)
- MAC 47.78
- ZLAB 42.71
- Support Level
- MAC $14.84
- ZLAB $27.61
- Resistance Level
- MAC $15.32
- ZLAB $32.02
- Average True Range (ATR)
- MAC 0.48
- ZLAB 1.23
- MACD
- MAC 0.17
- ZLAB -0.18
- Stochastic Oscillator
- MAC 75.54
- ZLAB 23.41
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 30 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.9 million square feet of gross leasable area and averaged $837 sales per square foot over the 12 months ended in December 2024.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.